The study focused on 5% and 7.5% solutions of AN2690 in onychomycosis, a fungal infection of the nail and nail bed.
At six months, halfway through the study, 50% of patients in the 7.5% group and 45% of patients in the 5% dose group met the primary endpoint of the study, which was more than 2 mm of clear nail growth and a negative fungal culture.
Subjects were treated once daily with AN2690, a topical antifungal drug, and evaluated for both a clinical response by measuring the length of new clear nail growth as well as for the presence of fungi by culture and direct microscopic evaluation.
“These results suggest that the AN2690 is substantially more effective that other topical treatments and could rival results seen with the currently available oral treatments,” said Raza Aly, adjunct professor in the departments of dermatology and microbiology immunology at the University of California. “The mycological findings clearly show that the drug kills fungus, and the consistent clear nail growth provides evidence of a real clinical benefit from the treatment.”
As is the practice in onychomycosis trials these subjects will be followed for an additional six months. This type of follow-up is required to allow the nail time to regrow after the fungus has been eliminated.